MOHAMED, Lounis, Rais Mohammed AMIR, Bencherit DJIHAD, Aouissi Hani AMIR, Oudjedi ADDA, Jitka KLUGAROVÁ, Andrea POKORNÁ, Miloslav KLUGAR a Abanoub RIAD. Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers. Frontiers in Public Health. LAUSANNE: FRONTIERS MEDIA SA, 2022, roč. 10, May 2022, s. 1-12. ISSN 2296-2565. Dostupné z: https://dx.doi.org/10.3389/fpubh.2022.896343.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers
Autoři MOHAMED, Lounis, Rais Mohammed AMIR, Bencherit DJIHAD, Aouissi Hani AMIR, Oudjedi ADDA, Jitka KLUGAROVÁ (203 Česká republika, domácí), Andrea POKORNÁ (203 Česká republika, domácí), Miloslav KLUGAR (203 Česká republika, domácí) a Abanoub RIAD (818 Egypt, garant, domácí).
Vydání Frontiers in Public Health, LAUSANNE, FRONTIERS MEDIA SA, 2022, 2296-2565.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30304 Public and environmental health
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 5.200
Kód RIV RIV/00216224:14110/22:00125821
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3389/fpubh.2022.896343
UT WoS 000803613500001
Klíčová slova anglicky adenoviral-based vaccine; COVID-19; health workers; inactivated virus vaccine; side effects
Štítky 14110525, 14110611, 14119612, 14119613, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 5. 4. 2023 08:16.
Anotace
Healthcare workers were prioritized in vaccination campaigns globally because they are exposed to the highest risk of contamination by SARS-CoV-2. This study evaluated the self-reported post-vaccination side effects of inactivated (BBIBP-CorV and CoronaVac) and adenoviral vector-based (AZD1222, Gam-COVID-Vac and Ad26.COV2.S) vaccines among Algerian healthcare workers using a validated questionnaire. The final analysis included 721 healthcare workers, with a predominance of females (59.1%) and younger individuals 20–30 years old (39.4%). Less than half (49.1%) of the respondents reported at least one local side effect, while 53.8% reported at least one systemic side effect. These side effects were more prevalent among viral vector vaccinees than inactivated virus vaccinees. The most common local side effects were injection site pain (39%) and arm pain (25.4%), while fatigue (34.4%), fever (28.4%), headache (24.8%) and myalgia (22.7%) were the most prevalent systemic side effects. The side effects appeared earlier among inactivated virus vaccines recipients and generally lasted for 2 to 3 days for the two vaccinated groups. The risk factors associated with a higher prevalence of side effects included female gender, allergic individuals, individuals with regular medication, those who contracted the COVID-19 disease and those who received two doses for both inactivated and viral-based vaccines groups. Despite the higher prevalence of post-vaccination side effects among adenoviral vector vaccines recipients, both vaccines groups were equally effective in preventing symptomatic infections, and no life-threatening side effects were reported in either vaccine group.
Návaznosti
EF19_073/0016943, projekt VaVNázev: Interní grantová agentura Masarykovy univerzity
LTC20031, projekt VaVNázev: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic, INTER-COST
MUNI/A/1402/2021, interní kód MUNázev: Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu IV
Investor: Masarykova univerzita, Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu IV
MUNI/IGA/1104/2021, interní kód MUNázev: COVID-19 Vaccines Safety Tracking in the Czech Republic (Akronym: CoVaST-CZ)
Investor: Masarykova univerzita, COVID-19 Vaccines Safety Tracking in the Czech Republic
VytisknoutZobrazeno: 25. 4. 2024 04:00